Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
One Biosciences receives €3.3 million funding to accelerate the development of its single-cell diagnostic for triple-negative breast cancer. The funding is part of the i-Démo 5 program from France 2030.
PRIVATESep 10, 2026•about 3 hours ago
Amount Raised
€3.3 Million
Round Type
Seed
ParisBiotechnology
Investors
France 2030
Description
One Biosciences has secured €3.3 million to support the development of its first single-cell profiling diagnostic for triple-negative breast cancer. This funding is provided under the i-Démo 5 initiative from France 2030. The program aims to enhance treatment decisions for this challenging cancer type. This collaboration with Institut Curie underscores the importance of innovative diagnostics.
Company Information
Company
One Biosciences
Location
Paris, Ile-de-France, France
About
One Biosciences is a biotech company leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and develop new treatments. The company is advancing its pipeline across multiple ongoing projects in oncology and rare diseases.
Don't miss One Biosciences's next move
Get an email the moment One Biosciences raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for One Biosciences's next move
ParisBiotechnology